NovoCure (NVCR) Current Deferred Revenue (2015 - 2019)

NovoCure's Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $19.6 million for Q4 2019.

• In Q4 2019, Current Deferred Revenue rose 4.32% year-over-year to $19.6 million; the TTM figure through Dec 2019 stood at $19.6 million (up 4.32% YoY), while the FY2019 annual figure was $19.6 million, up 4.32% from the prior year.
• Current Deferred Revenue came in at $19.6 million for Q4 2019 at NovoCure, up from $18.8 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $19.6 million in Q4 2019 to a low of $52000.0 in Q4 2015.
• A 5-year average of $9.1 million and a median of $5.0 million in 2017 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 4259.62% in 2016 and grew 4.32% in 2019, its largest moves.
• NovoCure's Current Deferred Revenue stood at $52000.0 in 2015, then jumped by 4259.62% to $2.3 million in 2016, then soared by 118.75% to $5.0 million in 2017, then jumped by 278.48% to $18.8 million in 2018, then climbed by 4.32% to $19.6 million in 2019.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $19.6 million, $18.8 million, and $5.0 million for Q4 2019, Q4 2018, and Q4 2017 respectively.

Peer Comparison